GPhA Objection To Generic Drug Rule Could Backfire, FDA Counsel Troy Warns
This article was originally published in The Tan Sheet
Executive Summary
The generic drug industry should carefully consider any attempt to derail FDA's regulatory approach to Hatch/Waxman reform, agency Chief Counsel Daniel Troy told the Generic Pharmaceutical Association
You may also be interested in...
FDA Adds Patent Declaration Forms For Innovators To Generic Final Rule
Patent declaration forms must be used for Orange Book submission of patent information under FDA's generic reform final rule
30-Month Stay Proposal Would Delay Generics, Should Be Withdrawn, GPhA Says
FDA's proposed rule on 30-month stays would discourage timely suits by brand-name firms and should not be implemented, according to the Generic Pharmaceutical Association
FDA Patent Listing Criteria Allow Polymorph, Product-By-Process Claims
FDA's proposed reforms to the Orange Book patent listing procedures would allow companies to list patents covering polymorphs and some types of manufacturing processes